All In Biotech

Drug Trial Radar · NCT02892149

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE-CONVERSION)

Last checked: Nov 20, 2026Latest source record: Jun 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,554 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,554

Actual

Start

Aug 2016

Primary completion

Jan 16, 2020

Study completion Mar 30, 2020

Sponsor

Lead sponsor
Akebia TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with dialysis-dependent chronic kidney disease (DD-CKD)

Conditions

  • Anemia
  • Dialysis-Dependent Chronic Kidney Disease

Interventions

  • VadadustatDrug

    Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

  • Darbepoetin alfaDrug

    Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)Time frame: Baseline; Weeks 24 to 36
  2. Median Time to First Major Adverse Cardiovascular Event (MACE)Time frame: Up to 170 weeks

Locations

278 sites in 18 countries. Site status is shown where the registry gives one.

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mesa, Arizona

  • Research Site

    Pine Bluff, Arkansas

  • Research Site

    Anaheim, California

  • Research Site #1

    Bakersfield, California

  • Research Site #2

    Bakersfield, California

  • Research Site

    Canyon Country, California

  • Research Site

    Chula Vista, California

  • Research Site

    Downey, California

  • Research Site

    El Centro, California

  • Research Site

    Escondido, California

  • Research Site

    Fairfield, California

  • Research Site

    Glendale, California

  • Research Site #1

    Granada Hills, California

  • Research Site #2

    Granada Hills, California

  • Research Site

    La Habra, California

  • Research Site

    La Mesa, California

  • Research Site

    Lakewood, California

  • Research Site

    Long Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site #1

    Montebello, California

  • Research Site

    Monterey Park, California

  • Research Site

    Newhall, California

  • Research Site #1

    Northridge, California

  • Research Site #2

    Northridge, California

  • Research Site

    Riverside, California

  • Research Site

    Riverside, California

  • Research Site

    Roseville, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site #1

    San Dimas, California

  • Research Site #2

    San Dimas, California

  • Research Site

    Simi Valley, California

  • Research Site

    Tarzana, California

  • Research Site

    Whittier, California

  • Research Site

    Whittier, California

  • Research Site

    Arvada, Colorado

Showing 40 of 278 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.